EQL Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is April - March.

Millions SEK. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	48.69	67.37	32.62	41.34	35.97
Other Adjustments	-7.39	-0.5	-1.09	14.11	13.05
Change in Receivables	22.24	-67.15	-14.25	-16.86	-11.69
Changes in Inventories	-21.5	-73.41	-40.26	-23.69	0.68
Changes in Accounts Payable	-13.68	49.04	11.54	12.72	3.83
Operating Cash Flow	28.36	-24.65	-11.44	27.62	41.83
Operating Cash Flow Growth	-	-	-	-33.98%	-30.34%
Capital Expenditures	-5.44	-6.13	-0.93	-0.46	-0.63
Purchases of Intangible Assets	-61.8	-239.72	-65.34	-20.05	-21.46
Investing Cash Flow	-67.24	-245.84	-66.26	-20.51	-22.09
Long-Term Debt Issued	9.76	357.94	53.97	0	0.6
Long-Term Debt Repaid	-	-25.71	-0.49	-4.07	-6.58
Net Long-Term Debt Issued (Repaid)	9.76	332.23	53.48	-4.07	-5.98
Issuance of Common Stock	31.76	-	-	-	-
Net Common Stock Issued (Repurchased)	31.76	-	-	-	-
Other Financing Activities	1.73	0.19	0.27	0.19	0.86
Financing Cash Flow	43.24	332.43	53.74	-3.88	-5.12
Net Cash Flow	4.36	61.93	-23.96	3.23	14.62
Free Cash Flow	22.92	-30.78	-12.36	27.16	41.2
Free Cash Flow Growth	-	-	-	-34.08%	-31.39%
FCF Margin	5.30%	-8.24%	-4.68%	10.45%	10.06%
Free Cash Flow Per Share	0.76	-1.03	-0.41	0.92	1.39
Levered Free Cash Flow	-18.33	344.86	46.54	15.42	29.46
Unlevered Free Cash Flow	-7.09	22.95	-3.75	21.37	37.95